Jacobs Journal of Cancer Science and Research

Therapeutic approach to CML in TKI era

Published on: 2017-12-01


Chronic myeloid leukemia is a cancer that affects the cells of the bone marrow. These effected cells can grow and divide rapidly and spill into other parts of the body. It is relatively prevalent in the United States with 14% of cancer diagnoses being for CML. Immunotherapy is a new way to fight this cancer. The new era in the management of CML has started with the advent Tyrosine kinase inhibitors. This therapy stimulates one’s own immune system to fight the malignant tumor. We can classify the immunotherapeutics into TKI therapies and non TKI therapies broadly. In this paper, we discussed the causes, epidemiology, and potential immunotherapeutic techniques to treat CML.


Chronic Myeloid Leukemia; Cancer; Immunotherapy